Skip to content
Subscriber Only

Botox Rival Stays on U.S. Market After Court Order; Evolus Rises

  • Evolus gets temporary reprieve to continue selling Jeuveau
  • AbbVie, MedyTox had won import ban on Jeuveau in December

Evolus Inc. rose after its rival to the Botox wrinkle treatment was allowed to remain for sale in the U.S. temporarily while an appeals court considers staying an import ban won by AbbVie Inc.’s Allergan that was to go into effect Tuesday.

Daewoong Pharmaceutical Co. and Evolus filed the request early Saturday, urging the U.S. Court of Appeals for the Federal Circuit to put on hold on the ban against their treatment, Jeuveau. Allergan and its South Korean partner MedyTox Inc. in December won a ruling that Jeuveau is made using MedyTox’s secret process to turn the deadly botulinum toxin into a cosmetic product.